Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens.

Am J Vet Res

Institute of Pharmacology and Toxicology, Consejo Superior de Investigaciones Cietificas, Department of Toxicology and Pharmacology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Spain.

Published: July 2002

Objectives: To determine pharmacokinetic characteristics of marbofloxacin after a single IV and oral administration and tissue residues after serial daily oral administration in chickens.

Animals: 40 healthy broiler chickens.

Procedure: Two groups of chickens (groups A and B; 8 chickens/group) were administered a single IV and oral administration of marbofloxacin (2 mg/kg). Chickens of group C (n = 24) were given serial daily doses of marbofloxacin (2 mg/kg, PO, q 24 h for 3 days). Plasma (groups A and B) and tissue concentrations (group C) of marbofloxacin and its major metabolite N-desmethyl-marbofloxacin were determined by use of high-performance liquid chromatography. Residues of marbofloxacin and N-desmethylmarbofloxacin were measured in target tissues.

Results: Elimination half-life and mean residence time of marbofloxacin in plasma were 5.26 and 4.36 hours after IV administration and 8.69 and 8.55 hours after oral administration, respectively. Maximal plasma concentration was 1.05 microg/ml, and interval from oral administration until maximum concentration was 1.48 hours. Oral bioavailability of marbofloxacin was 56.82%. High concentrations of marbofloxacin and N-desmethyl-marbofloxacin were found in the kidneys, liver, muscles, and skin plus fat 24 hours after the final dose of marbofloxacin; however, marbofloxacin and N-desmethyl-marbofloxacin were detected in only hepatic (27.6 and 98.7 microg/kg, respectively) and renal (39.7 and 69.1 microg/kg, respectively) tissues 72 hours after termination of marbofloxacin treatment.

Conclusions And Clinical Relevance: Analysis of pharmacokinetic data obtained in this study reveals that a minimal therapeutic dose of 2 mg/kg, PO, every 24 hours should be appropriate for control of most infections in chickens.

Download full-text PDF

Source
http://dx.doi.org/10.2460/ajvr.2002.63.927DOI Listing

Publication Analysis

Top Keywords

oral administration
20
marbofloxacin
12
pharmacokinetic characteristics
8
tissue residues
8
residues marbofloxacin
8
metabolite n-desmethyl-marbofloxacin
8
single oral
8
serial daily
8
marbofloxacin mg/kg
8
hours oral
8

Similar Publications

Introduction: Pain at the buccal mucosal graft (BMG) harvest site in the immediate postoperative period is common and delays resumption of oral intake. This study compares the time for resumption of pain-free solid and liquid diets and postoperative pain scores at harvest site following the administration of inferior-alveolar nerve-block plus buccal-nerve block (IANB + BNB) versus placebo. We hypothesize that the intervention could decrease pain and aid in early food intake.

View Article and Find Full Text PDF

Targeting Ribosome Biogenesis for Cancer Therapy with Oral Platinum Complexes.

JACS Au

January 2025

School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), State Key Laboratory of Coordination Chemistry, Najing University, Nanjing 210023, PR China.

Cancer cells often upregulate ribosome biogenesis to meet increased protein synthesis demands for rapid proliferation; therefore, targeting ribosome biogenesis has emerged as a promising cancer therapeutic strategy. Herein, we introduce two Pt complexes, ataluren monosubstituted platinum(IV) (SPA, formula: c,c,t,-[Pt(NH)Cl(OH)(CHFNO)], where CHFNO = ataluren) and ataluren bisubstituted platinum(IV) complex (DPA, formula: c,c,t,-[Pt(NH)Cl(CHFNO)], where CHFNO = ataluren), which effectively suppress ribosome biogenesis by inhibiting 47s pre-RNA expression. Furthermore, SPA and DPA induce nucleolar stress by dispersing nucleolar protein NPM1, ultimately inhibiting protein generation in tumor cells.

View Article and Find Full Text PDF

Purpose: To improve the oral absorption of relugolix (RLGL), which has low oral bioavailability due to its low solubility and being a substrate of P-glycoprotein (P-gp). A solid self-microemulsifying drug delivery system of relugolix (RLGL-S-SMEDDS) was prepared and evaluated in vitro and in vivo.

Methods: The composition of the solid self-microemulsifying drug delivery system (S-SMEDDS) was selected by solubility study and pseudo-ternary phase diagram, and further optimized by Design-Expert optimization design.

View Article and Find Full Text PDF

Development of Chitosan-Polyacrylic Acid Complex Systems for Enhanced Oral Delivery of and Probiotics.

Drug Des Devel Ther

January 2025

Department of Pharmaceutical Sciences and Pharmaceutics, Faculty of Pharmacy, ‎Applied ‎Science Private University, Amman, 11937, Jordan.

Introduction: The beneficial effects of probiotics are encountered by their low viability in gastrointestinal conditions and their insufficient stability during manufacturing, throughut the gastrointestinal transit, and storage. Therefore, novel systems are highly required to improve probiotics delivery.

Methods: In this study, Lactobacillus gasseri (L), Bifidobacterium bifidum (B), and a combination of L+B were encapsulated in chitosan (CS)-polyacrylic acid (PAA) complex systems (CS-PAA).

View Article and Find Full Text PDF

Background: Rickets is a common metabolic bone disease in children, primarily caused by vitamin D deficiency. This study aimed to compare the efficacy of oral weekly vitamin D supplementation and injectable stoss therapy in treating nutritional rickets in Indian children.

Methods: This prospective, randomized, controlled trial was conducted over 18 months at a tertiary care center.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!